Tolvaptan was evaluated in 2 identical multicenter, randomized, double-blinded, placebo-controlled studies enrolling 448 patients with euvolemic or hypervolemic hyponatremia, as titiled, Study of Ascending Levels of Tolvaptan in Hyponatremia (SALT-1 and -2)
16). In SALT-1 and -2 studies, patients were randomly assigned to receive tolvaptan at 15 mg for 30 days once daily titrated up to 60 mg if needed, or placebo for 30 days once daily. Eligible patients were 18 years and older with euvolemic and hypervolemic hyponatremia (defined as a serum Na
+ < 135 mEq/L) of congestive heart failure, liver cirrhosis, and SIADH. Ineligible diseases and conditions of patients were hypovolemic hyponatremia, pychogenic polydipsia, head trauma, postoperative conditions, uncontrolled hypothyroidism, adrenal insufficiency, and medication-induced hyponatremia were excluded. Other exclusion criteria included the presence of ventricular arrhythmias, systolic blood pressure < 90 mmHg, serum creatinine > 3.5, Child-Pugh score > 10, serum Na
+ < 120 mEq/L, uncontrolled diabetes, or other neurologic diseases. Patients were allowed to continue conventional therapy of heart failure (even diuretics), and if the Na
+ rose > 145 or > 12 mEq/L within 24 hours, the next dose of tolvaptan was stopped or decreased, or the investigators allowed the subjects to increase fluid intake. The increase in the average daily area under the curve (AUC) for the Na
+ concentration was significantly higher in the tolvaptan group than in the placebo group from baseline to study day 4, and day 30 (
P < 0.001). In subgroup analysis categorized to mild hyponatremia (130 to 135 mEq/L) or marked hyponatremia (< 130 mEq/L) at baseline, the tolvaptan group showed a significantly greater increase in the average daily AUC for the serum Na
+ concentration (
P < 0.001). Within 8 hours after the first administration of tolvaptan, the serum Na
+ concentrations were significantly higher in the tolvaptan group than in the placebo group for both the total patient population and the subgroups categorized to degree of hyponatremia at baseline (all
P < 0.01). Significantly more patients in the tolvaptan-treated group had normal Na
+ values at 30 days than placebo (
P < 0.001). Urine output was significantly greater in the tolvaptan groups in both studies (
P < 0.001). The most common adverse events were thirst and dry mouth, and other adverse events included dizziness, hypotension, acute renal failure, sepsis, and ascites. After discontinuation of treatment, patients' Na
+ values decreased in both the tolvaptan and placebo groups and there was no statistical difference.
The long term use of tolvaptan in chronic hyponatremia was assessed in The Safety and sodium Assessment of Long-term Tolvaptan With hyponatremia: A year-long, open-label Trial to gain Experience under Real-world conditions (SALTWATER) study
17). The SALTWATER study was an international, multicenter, nonrandomized, open-label extension of SALT-1 and -2 studies. In total, 111 patients with hyponatremia received oral tolvaptan for a mean follow-up of 701 days, providing 77,369 patient-days of exposure. Eligible patients had hyponatremia, finished SALT-1 and SALT-2 studies and wanted to continue tolvaptan therapy. Mean serum Na
+ of patients increased from 130.8 mEq/L at baseline to more than 135 mEq/L during the study duration (
P < 0.001). Serum Na
+ in most patients of SIADH and heart failure was relatively well maintained at > 135 mEq/L compared to patients with liver cirrhosis. The most common adverse effects were pollakiuria, thirst, dry mouth, and polyuria. Six patients withdrew due to drug-related adverse effects including severe ventricular tachycardia, severe irritability, mild serum sodium increase, mild anorexia, severe azotemia, and moderate pruritus. Rapid correction of serum sodium (> 1 mEq/L/hr) occurred in 5 patients. Hypernatremia (> 145 mEq/L) was observed in one patient. This study showed that prolonged use of tolvaptan could maintain increased serum Na
+ and also could have a modest safety margin in chronic hyponatremia.
The Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) trials was 2 multicenter, randomized, double-blind, placebo-controlled studies that evaluated the effects of tolvaptan in patients hospitalized with heart failure (HF)
18-
20). In total, 4,133 patients were enrolled and randomized to receive tolvaptan (30 mg/day) or placebo group, both groups were allowed the standard HF therapy, within 48 hours of admission. The mean follow-up time was 9.9 months. The withdrawal rate and adverse events (predominantly due to dry mouth and thirst) in both groups were similar. Rapid improvement of signs and symptoms was seen in the tolvaptan group without serious adverse events. However, there was no difference in the primary endpoints of all causes of mortality, the composite of cardiovascular death and HF hospitalization, or overall quality of life scores between the groups. Therefore, in HF patients, tolvaptan could not be initial standard therapy because of the evidence seen from EVEREST. Tolvaptan has not received approval from the United States Food and Drug Administration for this indication.